Inflammation-Inducible Anti-TNF Vector for Ocular Uveitis Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic inflammatory eye diseases like uveitis, such as corticosteroids and immunosuppressants, are associated with significant adverse effects and require frequent administration due to the recurrent nature of the condition, while biologics like TNF inhibitors have their own risks.
Innovation Solution
A gene therapy vector encoding a TNF inhibitor under the control of an inflammation-inducible promoter for targeted expression in the eye, providing an adaptable and responsive dose to prevent or treat inflammatory eye diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If corticosteroids are administered systemically to treat uveitis, then the therapeutic effect is improved, but adverse effects increase
Solution Approach 1:
The patent applies local quality by transitioning from systemic corticosteroid administration to localized intraocular delivery through intravitreal injection or implantation. This concentrates the therapeutic agent directly at the site of inflammation (the eye), achieving effective local treatment while minimizing systemic exposure and associated adverse effects such as osteoporosis, diabetes, and hypertension.
Solution Approach 2:
The patent uses biodegradable polymer implants as an intermediary delivery system. These implants serve as a mediator that provides sustained local release of corticosteroids or immunosuppressants within the vitreous humor, maintaining therapeutic concentrations over time without requiring repeated injections or systemic administration.
2Reliability
If corticosteroids are administered locally via repeat injections to treat uveitis, then the therapeutic effect is maintained, but device complexity and treatment frequency increase
Solution Approach 1:
The patent implements continuity of useful action through sustained-release implants that continuously deliver therapeutic agents over extended periods (months to years). This eliminates the need for repeated periodic injections, providing continuous anti-inflammatory coverage and maintaining stable drug concentrations at the treatment site without interruption.
Solution Approach 2:
The patent applies preliminary action by pre-loading therapeutic agents into biodegradable polymer implants before implantation. The implants are prepared in advance with controlled-release formulations that automatically release drugs over time, eliminating the need for repeated clinical interventions and providing prolonged therapeutic effect from a single administration.
3Reliability
If immunosuppressant therapy is used to treat uveitis, then the therapeutic effect is improved, but adverse effects increase
Solution Approach 1:
The patent applies local quality by delivering immunosuppressant agents directly into the ocular compartment through implants. This localized delivery achieves effective suppression of intraocular inflammation while minimizing systemic immunosuppression, thereby reducing adverse effects such as increased infection risk, malignancy, and autoimmune disorders associated with systemic immunosuppressant therapy.
4Reliability
If TNF inhibitors are administered systemically to treat uveitis, then the therapeutic effect is improved, but adverse effects increase
Solution Approach 1:
The patent applies local quality by developing ocular-specific delivery systems for TNF inhibitors through intravitreal injection or implantation. This localized administration achieves effective blockade of TNF-mediated inflammation in the eye while minimizing systemic exposure, thereby reducing adverse effects such as autoimmune reactions, infections, malignancy risk, and demyelinating disorders associated with systemic TNF inhibitor therapy.
5Object-affected harmful factors
If local treatment options are used to treat uveitis, then adverse events are reduced, but manufacturing precision requirements increase
Solution Approach 1:
The patent applies parameter changes by utilizing biodegradable polymer matrices with controlled degradation rates to regulate drug release kinetics. By adjusting polymer composition, molecular weight, crosslinking density, and drug loading parameters, the implants provide precisely controlled release profiles that maintain therapeutic drug concentrations over time, ensuring accurate dosage delivery while minimizing adverse events.
Data Source
AI summary
The present invention provides a vector comprising a nucleotide sequence encoding an anti-TNF antibody or a fragment thereof, wherein the nucleotide sequence encoding the anti-TNF antibody or a fragment thereof is operably linked to an inflammation-inducible promoter.